TICKERNERD
Menu
GKOSGKOSHealthcare · Medical Devices

GKOS Stock Forecast: Glaukos Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$247
+5.86% on the day

The 13 Wall Street analysts covering Glaukos Corp. hold a median 12-month price target of $241 — -2.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 3 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$14.6B
Ticker Nerd rank
94/ 100
Median analyst target
$241
Analysts covering
13
Revenue$185.6M+49.5% y/y
Operating income−$15.8M
Net income−$18.4M
Free cash flow$12.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+36.0%
1M
+50.7%
YTD
+118.5%
1Y
+187.0%
From 52W high
0.0%
From 52W low
+201.6%
$82
$247
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GKOS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Glaukos Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
94/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
100
Accruals
94
Momentum
93
Volatility
82
Growth
65
Quality
64
Value
61
Issuance
54
Size
12

Revisions (100): Analysts have, on balance, been raising their forecasts.

Issuance (54): The company has been issuing shares or taking on financing, diluting existing holders.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GKOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GKOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250$300Jan 26Apr 26Jul 26Oct 26GKOSHigh $270Median $241Low $225

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $225Median $241High $270

The green dot is the last close — the median target sits −2.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Oct 2026BTIGMaintainsBuy$205 → $234
29 Oct 2026CitigroupMaintainsBuy$225 → $247
29 Oct 2026HC Wainwright & Co.MaintainsBuy$195 → $248
29 Oct 2026JP MorganMaintainsOverweight$200 → $240
29 Oct 2026NeedhamMaintainsBuy$201 → $251
29 Oct 2026Piper SandlerReiteratesOverweight$195 → $240
29 Oct 2026StifelMaintainsBuy$190 → $225
29 Oct 2026Truist SecuritiesMaintainsBuy$215 → $255
29 Oct 2026Wells FargoMaintainsOverweight$178 → $226
12 Oct 2026BTIGMaintainsBuy—
12 Oct 2026BTIGMaintainsBuy$202 → $205
22 Sept 2026JefferiesMaintainsBuy—
22 Sept 2026JefferiesMaintainsBuy$190 → $210
20 Aug 2026BTIGMaintainsBuy$193 → $202
20 Aug 2026BTIGMaintainsBuy—
30 July 2026BTIGMaintainsBuy—
30 July 2026BTIGMaintainsBuy$164 → $193
30 July 2026CitigroupMaintainsBuy—
30 July 2026CitigroupMaintainsBuy$175 → $188
30 July 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GKOS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GKOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Glaukos Corp. returned +187.0% against +12.9% for the S&P 500, dividends included.

GKOS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26GKOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GKOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
12
Analysts cutting
0
Fundamentals

Glaukos Corp. (GKOS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−75.1×

Cheaper than 99% of US stocks

Price / sales
21.2×

Cheaper than 8% of US stocks

Price / book
20.3×

Cheaper than 5% of US stocks

EV / EBITDA
−677.5×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
58.0%

Higher than 88% of US stocks

Earnings growth (YoY)
49.5%

Higher than 75% of US stocks

Gross margin
81.7%

Higher than 92% of US stocks

Operating margin
0.4%

Higher than 46% of US stocks

Net margin
−24.6%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−22.8%

Higher than 30% of US stocks

Return on assets
−3.9%

Higher than 34% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Glaukos Corp. (GKOS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Glaukos Corp. has a market value of $14.6B and an enterprise value of $13.6B.

  • Revenue in the twelve months to 30 June 2026: $612.8M. The latest quarter grew 58.0% year on year.

  • Net income over the same four quarters: −$188.0M, a −30.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.25.

  • Free cash flow in the twelve months to 30 June 2026: −$28.8M.

  • Shares outstanding: 58.9M.

  • Trailing P/E: −75.1×; forward P/E: 176.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Glaukos Corp. employs 1,094 people — $560K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

GKOS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GKOSGlaukos Corp.$14.6B94
PENPenumbra, Inc.$12.6B76
PODDInsulet Corp.$10.7B91
GMEDGlobus Medical, Inc.$10.7B97
BIOBio-Rad Laboratories, Inc.$10.0B92
ZBHZimmer Biomet Holdings, Inc.$19.2B90
BRKRBruker Corp.$8.6B90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Glaukos Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GKOS news & analysis

Glaukos Announces Participation in Upcoming Investor Conferences

Business Wire · 3 Nov 2026neutral

Glaukos announced that management is scheduled to participate in upcoming investor conferences, including the Stifel Healthcare Conference on November 10, 2026, in New York City. The excerpt also names the Jefferies Global Healthcare Conference but does not provide its full schedule.

Why it matters — The announcement informs GKOS watchers about planned opportunities for management to engage with investors.

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PRNewsWire · 30 Oct 2026neutral

Effective before trading on November 4, Glaukos will move from the S&P SmallCap 600 to the S&P MidCap 400, replacing Okta. McGrath RentCorp will replace Glaukos in the S&P SmallCap 600.

Why it matters — GKOS watchers may note the announced change in Glaukos’s S&P index membership.

Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction

The Motley Fool · 29 Oct 2026positive

Glaukos raised its 2026 sales forecast to $775 million–$785 million and set a preliminary 2027 sales target of $1 billion, following a 58% year-over-year increase in third-quarter sales to $211.0 million. The excerpt notes that profit is thinner than adjusted figures suggest.

Why it matters — The updated sales outlook and quarterly growth are relevant to GKOS watchers, while the profit caveat adds context to the results.

Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings

Benzinga · 29 Oct 2026positive

Glaukos reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates. The headline says analysts boosted their forecasts following the results.

Why it matters — GKOS watchers may note the quarterly results and higher sales guidance, as well as the reported analyst forecast increases.

FAQ

Frequently asked questions about GKOS stock

What is the GKOS stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Glaukos Corp. have a median 12-month price target of $241, with estimates ranging from $225 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GKOS stock a buy right now?

Of the 13 analysts covering Glaukos Corp., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Glaukos Corp. 94 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GKOS?

As at 3 Nov 2026, Glaukos Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (100 of 100).

Will GKOS stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies -2.3% from the last close, and Ticker Nerd's factor model ranks Glaukos Corp. 94 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GKOS stock forecast for 2030?

No analyst covering Glaukos Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GKOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $225 to $270 over the next 12 months.

How has GKOS stock performed over the past year?

Glaukos Corp. returned +187.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Glaukos Corp. do?

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases.

What is the latest news on GKOS?

The most recent item we track (Business Wire, 3 Nov 2026): "Glaukos Announces Participation in Upcoming Investor Conferences". Glaukos announced that management is scheduled to participate in upcoming investor conferences, including the Stifel Healthcare Conference on November 10, 2026, in New York City. The excerpt also names the Jefferies Global Healthcare Conference but does not provide its full schedule.

Company

About Glaukos Corp.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release drug delivery systems, and bio-activated therapies designed to address chronic eye disease across multiple stages of care. The company serves ophthalmologists, surgeons, and healthcare providers with solutions intended to improve treatment options in both surgical and pharmaceutical settings. Glaukos Corp. is a specialized participant in the eye care market, combining medical devices and medicines to support procedures and therapies used in glaucoma management and corneal health.

CEO Mr. Thomas William Burns · 1,094 employees · United States · https://www.glaukos.com